Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Albireo Pharma Inc | ALBO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
44.15 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 17.78 - 45.23 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 44.15 | USD |
Albireo Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 913.96M | - | - | - | -2,420.78 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Albireo Pharma News
Date | Time | Source | News Article |
---|---|---|---|
15/2/2023 | 00:30 | GlobeNewswire Inc. | FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay®.. |
21/12/2022 | 08:30 | GlobeNewswire Inc. | Albireo Reports Inducement Grant Under Nasdaq Listing Rule.. |
20/12/2022 | 00:30 | GlobeNewswire Inc. | Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings.. |
09/12/2022 | 04:35 | TipRanks | Wedbush Reaffirms Their Buy Rating on Albireo Pharma (ALBO) |
07/12/2022 | 08:30 | GlobeNewswire Inc. | Albireo Reports Inducement Grant Under Nasdaq Listing Rule.. |
07/12/2022 | 00:30 | GlobeNewswire Inc. | Albireo Appoints Paul Streck, M.D., as Chief Medical Officer.. |
Historical ALBO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Year | 21.91 | 45.23 | 17.78 | 41.29 | 503,848 | 22.24 | 101.51% |
3 Years | 36.97 | 45.23 | 16.02 | 30.38 | 278,108 | 7.18 | 19.42% |
5 Years | 25.33 | 52.90 | 11.26 | 30.33 | 202,295 | 18.82 | 74.3% |